These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24056704)

  • 1. Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs.
    Zhou X; Gao ZW; Meng J; Chen XY; Zhong DF
    Acta Pharmacol Sin; 2013 Nov; 34(11):1420-6. PubMed ID: 24056704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
    Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
    Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.
    Shin KH; Kim BH; Kim TE; Kim JW; Yi S; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Dec; 31(12):3009-20. PubMed ID: 20110038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of modulation of P-glycoprotein and /or cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered morphine in dogs.
    Gadeyne C; Van der Heyden S; Gasthuys F; Croubels S; Schauvliege S; Polis I
    J Vet Pharmacol Ther; 2011 Oct; 34(5):417-23. PubMed ID: 21241325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants.
    Tanaka C; Yin OQ; Smith T; Sethuraman V; Grouss K; Galitz L; Harrell R; Schran H
    J Clin Pharmacol; 2011 Jan; 51(1):75-83. PubMed ID: 20702754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
    Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
    Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
    Dutreix C; Munarini F; Lorenzo S; Roesel J; Wang Y
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1223-34. PubMed ID: 24085261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
    Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
    J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
    Kusawake T; den Adel M; Groenendaal-van de Meent D; Garcia-Hernandez A; Takada A; Kato K; Ohtsu Y; Katashima M
    Adv Ther; 2017 Nov; 34(11):2466-2480. PubMed ID: 29076107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.
    Garg V; Chandorkar G; Yang Y; Adda N; McNair L; Alves K; Smith F; van Heeswijk RP
    Br J Clin Pharmacol; 2013 Feb; 75(2):431-9. PubMed ID: 22642697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
    Xu H; O'Gorman M; Tan W; Brega N; Bello A
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1441-9. PubMed ID: 26381275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycyrrhizin accelerates the metabolism of triptolide through induction of CYP3A in rats.
    Tai T; Huang X; Su Y; Ji J; Su Y; Jiang Z; Zhang L
    J Ethnopharmacol; 2014 Mar; 152(2):358-63. PubMed ID: 24486211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of metabolites of GLS4 in humans using ultrahigh-performance liquid chromatography/quadrupole time-of-flight mass spectrometry.
    Zhou X; Li L; Deng P; Chen X; Zhong D
    Rapid Commun Mass Spectrom; 2013 Nov; 27(21):2483-92. PubMed ID: 24097405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
    Wang X; Wang J; Arora S; Hughes L; Christensen J; Lu S; Zhang ZY
    J Clin Pharmacol; 2019 Apr; 59(4):488-499. PubMed ID: 30422319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.
    Liu Y; Zhou S; Wan Y; Wu A; Palmisano M
    Br J Clin Pharmacol; 2014 Nov; 78(5):1050-7. PubMed ID: 24962564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.
    Shoaf SE; Bricmont P; Mallikaarjun S
    Br J Clin Pharmacol; 2012 Apr; 73(4):579-87. PubMed ID: 21988334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
    Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
    Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs.
    Kuroha M; Azumano A; Kuze Y; Shimoda M; Kokue E
    Drug Metab Dispos; 2002 Jan; 30(1):63-8. PubMed ID: 11744613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
    Martin P; Gillen M; Millson D; Oliver S; Brealey C; Grossbard EB; Baluom M; Lau D; Sweeny D; Mant T; Craven K
    Drugs R D; 2016 Mar; 16(1):81-92. PubMed ID: 26739683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
    Hatorp V; Hansen KT; Thomsen MS
    J Clin Pharmacol; 2003 Jun; 43(6):649-60. PubMed ID: 12817528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.